Anti-Infective Drugs Global Market Is Expected To Grow Close To $133 Billion By 2021 According To TBRC’s Latest Report

Infectious diseases are disorders caused by several pathogenic organisms such as bacteria, viruses, fungi or parasites. These diseases can be transmitted or spread from one person to another through direct contact or indirect contact. Anti-infective drugs are used to treat or prevent these infectious diseases by inhibiting the spread of an infectious agent (static) or by killing the infectious agent (cidal).

Read More: https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-global-market-report-2018

The major reason why the global anti-infective drugs market will increase from $117 billion in 2017 to $133 billion by 2021 is the growth of infectious diseases caused by bacteria, viruses, fungi and the expected increase in global healthcare expenditure.

In the report, the global anti-infective drugs market is divided into four segments, namely antivirals, antibiotics, antifungals and others (antihelmethic, antiprotozoal). While the first segment accounts for more than half of the market share, the remaining share is attributed to the other three segments.

Sample Report: https://www.thebusinessresearchcompany.com/sample.aspx?id=255&type=smp

The USA was the largest country in the anti-infective drugs market in 2017, accounting for nearly one-fourth of the market share. This can be attributed to the increased healthcare expenditure per capita in the country and the availability of a wide network of healthcare facilities. China and Italy followed the USA as the next largest countries in the market.

The anti-infective drugs market is fragmented into a number of large and small organizations. The top five competitors in the market made up around 30% of the total market in 2017. Gilead Sciences, Inc. was the largest competitor of the market, followed by Merck & Co. and GlaxoSmithKline Plc. Gilead is an American biopharmaceutical company that discovers, develops and commercializes therapeutics for areas such as cardiovascular and inflammation/respiratory diseases, hematology/oncology, human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection. The company was founded in 1987 and is headquartered in Foster City, California, United States.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Global Dermatology Drugs Market Is Expected To Grow Close To $42 Billion By 2021 According To TBRC’s Latest Report

The dermatology drugs market includes medications that are used for the treatment of skin conditions such as dermatitis (including eczema), rosacea, hyperhidrosis, androgenic alopecia, onychomycosis, hair loss, acne, immune disorders (including psoriasis), microbial infections (bacterial, fungal, and viral), vascular and pigmented lesion removal, common warts, seborrheic keratosis, and other skin diseases.

Read More: https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report-2018

The major reason why the global dermatology drugs market will increase from $33 billion in 2017 to close to $42 billion by 2021 is the increase in the number of indications treated by topical drugs

Sample Report:https://www.thebusinessresearchcompany.com/sample.aspx?id=251&type=smp

The USA was the largest country in the dermatology drugs market in 2017, accounting for nearly one-fourth of the market share. The factors attributed to the size of this market include high quality healthcare facilities, a high cost healthcare system and the GDP of the country. China and Japan followed the USA as the next largest countries in the market.

The dermatology drugs market is fragmented with a number of large and small drugs organizations. The top five competitors in the market made up around 45% of the total market in 2017. Johnson & Johnson was the largest competitor of the market, followed by Allergan Plc. and Galderma S.A. J&J was founded in 1886 and is headquartered in New Jersey, USA. The company is engaged in the development, manufacturing and marketing of personal care hygienic products, pharmaceuticals and surgical equipment.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Global Central Nervous System Drugs Market Is Expected To Grow To $90 Billion By 2021 According To TBRC’s Latest Report

The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities.

Read More:https://www.thebusinessresearchcompany.com/report/central-nervous-system-drugs-global-market-report-2018

The substantial growth of the market from $72 billion in 2017 to around $90 billion by 2021 is due to the steps taken by the US FDA (Food and Drug Administration) and EMA (European Medicines Agency) to offer allotment of special regulatory designations for Central Nervous System disorders which will help in the faster entry of drugs into the market for treatment of serious nervous system related conditions. The geriatric population and rise in diseases such as Parkinson’s, Alzheimer’s and other mental disorders is also likely to continue to drive the market for central nervous system drugs.

In the report, the global central nervous system drugs market is divided into five segments. Other CNS drugs occupy the major share, accounting for more than two-fifth of the market. Anaesthetics is the second largest segment, occupying one-fifth of the market share and the remaining two-fifth of the market share is occupied by the other three segments namely, analgesics, anti-parkinson drugs and anti-epileptics.

Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=258&type=smp

The USA was the largest country in the central nervous system drugs market in 2017, accounting for more than one-fourth of the market share. This can be attributed to high drug prices and increased healthcare spending in the USA compared to other countries. Germany and China followed the USA as the next largest countries in the market.

The central nervous system drugs market is fragmented with a number of large and small organizations. The top five competitors in the market made up around two-fifth of the total market in 2017. Biogen Inc. was the largest competitor of the market, followed by F. Hoffmann-La Roche Ltd., Johnson & Johnson, Pfizer Inc. and Novartis AG. Biogen Inc. was founded in 1978 and is headquartered in Massachusetts, USA. It is involved in discovering, developing, and selling medical products used to treat neurological disorders such as multiple sclerosis, and inflammatory diseases such as rheumatoid arthritis. Biogen Idec has offices in Australia, the Brazil, Japan, India, and China.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Global Metabolic Disorder Drugs Market Is Expected To Grow To $124 Billion By 2021 According To TBRC’s Latest Report

The metabolic disorders drugs market covers medications that are used in the treatment of metabolic diseases such as diabetes, thyroid, hyperparathyroidism, hypopituitarism, and hypoadrenalism. Some of the major drugs used in the treatment of metabolic diseases are Insulin, Methimazole, and Calcimimetics.

Read More:https://www.thebusinessresearchcompany.com/report/metabolic-disorders-drugs-global-market-report-2018

The substantial growth of the market from $90 billion in 2017 to $124 billion by 2021 is due to the rapid growth of diabetic patients which, according to the World Health Organization, is expected to be the world’s seventh leading cause of death in 2030.

In the report, the global metabolic disorder drugs market is divided into three segments. Anti-diabetic drug occupy the major share, accounting for more than 95% of the market and the remaining share is occupied by the other segments, namely, anti-thyroid drugs and others (hyperparathyroidism, hypopituitarism, hypoadrenalism).

Sample Report:https://www.thebusinessresearchcompany.com/sample.aspx?id=256&type=smp

The USA was the largest country in the metabolic disorder drugs market in 2017, accounting for nearly 35% of the market share. This was mainly due to large diabetic population and strong demand for anti-diabetics drugs in the country. China and Germany followed the USA as the next largest countries in the market.

The metabolic disorder drugs market is fragmented with a number of large and small organizations. The top five competitors in the market made up more than 35% of the total market in 2017. Sanofi S.A. was the largest competitor of the market, followed by Novo Nordisk A/S, AstraZeneca Plc., Johnson & Johnson and Merck & Co. Sanofi is a global life sciences company focused on vaccines, rare diseases, multiple sclerosis, immunology, oncology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. The company was founded in 1994 and is headquartered in Paris, France.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Global Hematology Drugs Market Is Expected To Grow By $52 Billion By 2021 According To TBRC’s Latest Report

Hematology drugs market offers drugs, blood and blood products that are used for the treatment of diseases such as rare genetic disorders, anemia, and conditions related to sickle cell disease and other related diseases. Some of the major hematology drugs include Albumin, Epoetin, Zoladex, and Hyskon.

Read the report at

https://www.thebusinessresearchcompany.com/report/hematology-drugs-global-market-report-2018

The substantial growth of the market from $40 billion in 2017 to around $52 billion by 2021 is due to the unhealthy lifestyle of consumers leading to anemia and coagulation disorders. Factors such as increased longevity and the launch of pipeline drugs will also drive the market for hematology drugs.

In the report, the hematology drugs market is divided into blood products and anemia and other blood disorder drugs, with blood products occupying the major market share (nearly 70%) and remaining is occupied by anemia and other blood products.

Download a sample of the report at

https://www.thebusinessresearchcompany.com/sample.aspx?id=254&type=smp

The USA was the largest country in the hematology drugs market in 2017, accounting for 30% of the market share. This was mainly due to high drug prices and high healthcare spending in the USA compared to other countries. China and Brazil followed the USA as the next largest countries in the market.

The hematology drugs market is fragmented with a number of large and small organizations. The top five competitors in the market made up around 25% of the total market in 2017. Novo Nordisk A/S was the largest competitor followed by Shire Plc., Bayer AG, Daiichi Sankyo Company Limited and Biogen Inc. Novo Nordisk A/S is a healthcare company involved in discovering, developing, manufacturing, and marketing of pharmaceutical products. Novo Nordisk markets and distributes its products through distributors and independent agents worldwide.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Genitourinary Drugs Global Market Is Expected To Grow Close To $82 Billion By 2021 According To TBRC’s Latest Report

The genitourinary drugs market covers drugs that are used in the treatment of diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, renovascular diseases, benign prostate diseases, and other related diseases.

Read the report at

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report-2018

The major reason why the global genitourinary drugs market will increase from $63 billion in 2017 to close to $82 billion by 2021 is growth of genitourinary disorders like chronic kidney disease CKD and the number of pipeline drugs.

In the report, the global genitourinary drugs market is divided into eight segments namely, hormonal contraceptives, drugs for hormonal replacement therapy, drugs for infections and others, drugs for benign prostatic hypertrophy, drugs for erectile dysfunction, drugs for urinary incontinence and overactive bladder, drugs for infertility, and diuretics. While the first and the second segments account for nearly three-fifth of the market share, the remaining share is attributed to the other six segments.

Download a sample of the report at

https://www.thebusinessresearchcompany.com/sample.aspx?id=253&type=smp

The USA was the largest country in the genitourinary drugs market in 2017, accounting for around 30% of the market share. This can be attributed to the high prevalence of urinary diseases like chronic kidney diseases, erectile dysfunction and infertility in the country. Moreover, public awareness and expenditure on health care is high in the USA. China and Italy followed the USA as the next largest countries in the market.

The genitourinary drugs market is fragmented with a number of large and small drugs organizations. The top five competitors in the market made up 14% of the total market in 2017. Daiichi Sankyo Company, Limited was the largest competitor of the market, followed by Pfizer Inc. and Bayer AG. Daiichi Sankyo Company is involved in the research, development and marketing of pharmaceutical products for osteoporosis, ulcer treatment, alzheimer’s disease, anti-influenza treatment, hypertension and diabetes. The company is headquartered in Tokyo, Japan and employs 14,670 people.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

The Global Oncology Drugs Market Is Excepted To Grow To $165 Billion By 2021 According To TBRC’s Latest Report

Oncology deals with diagnosis, prevention and treatment of cancer diseases. Anti-cancer or anti-neoplastic agents are the drugs that prevent or inhibit or halt the proliferation and maturation of neoplasms, an abnormal growth of tissues commonly referred as tumors.

Read the report at

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report-2018

The oncology drug market is expected to grow from $126 billion in 2017 to $165 billion by 2021 due to the increasing number of expensive but advanced and effective medications that will help in increasing the life expectancy of cancer patients.

The global oncology drugs market in The Business Research Company’s report is segmented into blood cancer, breast cancer, cervical cancer, lung cancer, colorectal cancer, non-small cell lung cancer, prostate cancer, kidney cancer, gastric cancer, brain tumor, pancreatic cancer, skin cancer, ovarian cancer, bladder cancer, thyroid cancer and others. While the first three segments account for more than two-fifth of the market share, the remaining is attributed to the remaining oncology drugs market segments.

Download a sample of the report at

https://www.thebusinessresearchcompany.com/sample.aspx?id=259&type=smp

The USA was the largest country in the oncology drugs market in 2017, accounting for almost one-fourth of the market share. This was the result of the medical facilities and health insurance schemes which allowed better accessibility to such drugs. The USA was followed by Germany and Japan.

F. Hoffmann-La Roche Ltd was the largest competitor in the oncology drugs market in 2017, followed by Novartis AG and Gilead Sciences, Inc. Roche is a multinational healthcare company that focuses on developing medicines and diagnostics. Roche’s growth strategy aims at increasing revenues from its laboratory business by introducing new medicines into the market.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Global Musculoskeletal Drugs Market Is Expected To Grow To $177 Billion By 2021 According To TBRC’s Latest Report

The musculoskeletal system drugs market comprises companies that discover, develop, manufacture and distribute medications used in the treatment of musculoskeletal diseases. Musculoskeletal diseases include arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus and others. Some of the major drugs in the market include Piroxicam Glaxo, Dolonex, Felden, and Piroxicam Pfizer.

Read the report at

https://www.thebusinessresearchcompany.com/report/musculoskeletal-disorders-drugs-global-market-report-2018

The substantial reason for the growth of the musculoskeletal system drugs market from $130 billion in 2017 to $177 billion in 2021. This can be attributed to the expected increase in healthcare awareness, number of surgical operations and prevalence of musculoskeletal disorders such as fibromyalgia, rheumatoid arthritis, osteoarthritis around the world.  Also, increasing number of road accidents and workplace injuries are expected to contribute to market growth. 

 North America was the largest region in the musculoskeletal disorders drugs market in 2017, accounting for almost one-third of the market share.

The market is segmented into: drugs for rheumatoid arthritis, muscle relaxants and others.

Download a sample of the report at

https://www.thebusinessresearchcompany.com/sample.aspx?id=257&type=smp

The USA was the largest country in the musculoskeletal disorders drugs market in 2017, accounting for almost one-sixth of the market share. This can be attributed to the increasing old age population and high per capita healthcare expenditure compared to other countries. The USA was followed by Japan and China.

The top five competitors in the market made up nearly 10% of the total market in 2017. F. Hoffmann-La Roche Ltd. was the largest competitor followed by GlaxosmithKline Plc., Pfizer Inc., Abbott Laboratories Inc. and Daiichi Sankyo Company Limited. F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. The company headquarters are located in Basel.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Global Ophthalmology Drugs Market Is Expected To Grow To $37 Billion By 2021 According To TBRC’s Latest Report

The ophthalmology drugs market covers drugs that are used in the treatment of eye related diseases such as refractive errors, cataracts, glaucoma, conjunctivitis, retinal diseases, and macular degeneration. Some of the major ophthalmic drugs include Eylea, Lucentis, Restasis, Vigamox, Azopt, and Lotemax.

Read More:

https://www.thebusinessresearchcompany.com/report/ophthalmology-drugs-global-market-report-2018

The substantial growth of the market from $27 billion in 2017 to $37 billion by 2021 is due to the expected rise in prevalence of eye conditions such as age-related macular degeneration (AMD), diabetic retinopathy and glaucoma that require ophthalmology drugs.

In the report, the global ophthalmology drugs market is divided into three segments. Other ophthalmology drugs occupy the major share in the market, accounting for nearly three-fifth of the market and the remaining segments, antiglaucoma drugs and dry eye medication occupy two-fifth of the market share.

Sample Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=260&type=smp

The USA was the largest country in the ophthalmology drugs market in 2017, accounting for more than one-fourth of the market share. This can be attributed to the high per capita healthcare expenditure and increasing geriatric population in the country. Germany and Japan followed the USA as the next largest countries in the market.

The ophthalmology drugs market is fragmented with a number of large and small organizations. The top five competitors in the market made up around 65% of the total market in 2017. Novartis AG was the largest competitor of the market, followed by F. Hoffmann-La Roche Ltd., Allergan Plc, Valeant Pharmaceuticals Intl Inc. and Bayer AG. Novartis is a multinational pharmaceutical company that develops, manufacture and markets healthcare products. The company was founded in 1970 and is headquartered in Basel, Switzerland.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info

Global Respiratory Drugs Market Is Expected To Grow To $71 Billion By 2021 According To TBRC’s Latest Report

Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral, Coldrex and Lemsip.

Read the report at

https://www.thebusinessresearchcompany.com/report/respiratory-diseases-drugs-global-market-report-2018

The substantial growth of the market from $55 billion in 2017 to nearly $71 billion by 2021 is due to the rise in global air pollution levels which will lead to higher number of respiratory diseases.

In the report, the global respiratory drugs market is divided into two segments, namely, anti-asthmatics and COPD drugs and cough and cold preparations. While the first segment accounts for more than three-fifth of the market and the remaining share is accounted for the other segment.

Download a sample of the report at

https://www.thebusinessresearchcompany.com/sample.aspx?id=261&type=smp

The USA was the largest country in the respiratory diseases drugs market in 2017, accounting for nearly two-fifth of the market share. This can be attributed to the large number of patients suffering from asthma and chronic obstructive pulmonary diseases (COPD).

The respiratory drugs market is fragmented with a number of small drug organizations. The top five competitors in the market made up nearly 50% of the total market in 2017. GlaxosmithKline Plc. was the largest competitor of the market, followed by AstraZeneca Plc., Merck & Co, Novartis AG and Johnson & Johnson. GlaxosmithKline Plc. was founded in 1715 and is headquartered in Brentford, UK. It is involved in creating, discovering, developing, manufacturing, and marketing of vaccines, over-the-counter medicines, and health-related consumer products globally.

About The Business Research Company.

The Business Research Company is a Business Intelligence Company which excels in company, market and consumer research. It has offices in the UK, the US and India and a network of trained researchers in 15 countries globally.

Contact Information.

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Email: info@tbrc.info